Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-VEC for Dystrophic Epidermolysis Bullosa
NCT04491604Phase 3Completed
- Sponsor
- Krystal Biotech, Inc.
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 3 trial of beremagene geperpavec in dystrophic epidermolysis bullosa (DEB), sponsored by Krystal Biotech, Inc.. Started Aug 2020; status: completed.
02
Drugs
beremagene geperpavec
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT04491604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491604.